Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Name: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
Published: 2021
License: Public Domain

Merck Sharp & Dohme LLC · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

non-small-cell-lung-cancer

non-small cell lung cancer, programmed cell death 1 (pd1, pd-1), programmed cell death-ligand 1 (pdl1, pd-l1), programmed cell death-ligand 2 (pdl2, pd-l2), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Related documents